CSPC Innovation Pharmaceutical (300765.SZ) subsidiary SYS6090 has initiated Phase Ib/II clinical trials.
Stone Pharmaceutical Innovation (300765.SZ) announced that its controlling subsidiary, Stone Pharmaceutical Group Jushi Biotechnology Co., Ltd. (referred to as "Jushi Biotechnology"), has recently initiated a Phase Ib/II clinical trial (SYS6090-007) to evaluate the safety, tolerability, and efficacy of SYS6090 injection in participants with hepatocellular carcinoma.
CSPC Innovation Pharmaceutical (300765.SZ) announced that its subsidiary CSPC PHARMA Jushi Biopharmaceutical Co., Ltd. ("Jushi Bio") has recently initiated a Phase Ib/II clinical trial (SYS6090-007) to evaluate the safety, tolerability, and efficacy of SYS6090 injection combined treatment in participants with hepatocellular carcinoma.
The launched SYS6090-007 clinical trial is an open-label, multicenter Phase Ib/II clinical trial aimed at assessing the safety, tolerability, and efficacy of the SYS6090 injection combined treatment in participants with hepatocellular carcinoma. Following the results of this study, the company will continue to advance the Phase III clinical research of SYS6090 injection combined treatment in hepatocellular carcinoma participants to further validate the efficacy and safety of SYS6090 injection. Currently, recruitment and screening of participants for the SYS6090-007 study are actively underway.
Related Articles
EVEREST GOLD (01815) issued 1 million shares due to the exercise of stock options.
KINGSOFT CLOUD (03896) announced its interim results, with adjusted EBITDA of 1.848 billion yuan, a year-on-year increase of 155.04%.
CHINA AEROSPACE (00031) issues a profit warning, expecting a net loss of approximately HKD 150 million to 180 million for the first half of the year.
EVEREST GOLD (01815) issued 1 million shares due to the exercise of stock options.
KINGSOFT CLOUD (03896) announced its interim results, with adjusted EBITDA of 1.848 billion yuan, a year-on-year increase of 155.04%.
CHINA AEROSPACE (00031) issues a profit warning, expecting a net loss of approximately HKD 150 million to 180 million for the first half of the year.
RECOMMEND
